Skip to main content

Table 2 Cox proportional hazard analyses of progression-free survival

From: Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

 

Univariate

Multivariate

Variables

Hazard ratio (95% CI)

p-value

Hazard ratio (95% CI)

p-value

Age, ≥ 65 years

1.47 (1.01–2.14)

0.041

1.46 (0.99–2.15)

0.056

Sex, men

1.02 (0.68–1.57)

0.941

  

Smoking, ever-smoker

1.27 (0.84–1.96)

0.257

  

ECOG-PS*

    

 0 vs. 1

0.71 (0.47–1.09)

0.114

0.98 (0.63–1.55)

0.928

 0 vs. ≥ 2

0.34 (0.18–0.71)

0.006

0.69 (0.34–1.53)

0.340

 1 vs. ≥ 2

0.48 (0.24–1.03)

0.059

0.70 (0.35–1.54)

0.358

Charlson comorbidity index*

    

 0 vs. 1

1.28 (0.83–2.05)

0.271

 0 vs. ≥ 2

0.79 (0.47–1.14)

0.407

 1 vs. ≥ 2

0.62 (0.33–1.18)

0.139

GNRI, ≥ 92

0.28 (0.18–0.46)

< 0.001

0.35 (0.21–0.58)

< 0.001

Pathology, squamous cell (vs. non-squamous)

1.20 (0.79–1.79)

0.390

  

Stage, IIIb (vs. IV/ recurrent)

0.85 (0.44–1.47)

0.575

  

Platinum agents, cisplatin (vs. carboplatin)

0.59 (0.35–0.95)

0.029

0.64 (0.37–1.06)

0.086

Non-platinum agents*

    

 Pemetrexed vs. taxane

0.62 (0.41–0.95)

0.028

0.85 (0.54–1.37)

0.509

 Pemetrexed vs. others

0.58 (0.35–0.98)

0.042

0.79 (0.45–1.40)

0.408

 Taxane vs. others

0.93 (0.57–1.55)

0.781

0.92 (0.55–1.56)

0.749

Treatment year, 2011–2020 (vs. 2000–2010)

0.56 (0.39–0.84)

0.005

0.65 (0.42–1.01)

0.053

  1. CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, GNRI Geriatric Nutritional Risk Index, PD-L1 programmed cell death-ligand 1, TPS tumor proportion score
  2. *Hazard ratio was calculated for each pair of three categorical units